Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 3

2(25.0%)

Phase 1

2(25.0%)

N/A

1(12.5%)

8Total

Phase 2(3)

Phase 3(2)

Phase 1(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07139873Phase 3Recruiting

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Role: lead

NCT07110103Phase 2Recruiting

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

Role: collaborator

NCT07079475Phase 1Recruiting

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Role: lead

NCT07154264Phase 2Recruiting

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Role: lead

NCT07182682Phase 3Recruiting

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Role: lead

NCT06864624Phase 2Recruiting

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Role: collaborator

NCT05559645Not ApplicableRecruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

Role: collaborator

NCT05176873Phase 1Completed

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Role: lead

All 8 trials loaded